{"date":"2026-07-01","count":15,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6814-2026-07-01-1752-1bvqtiv","company_id":"6814","company":"路迦生醫","market":"興櫃","industry":"生技醫療","date":"2026-07-01","time":"17:52:34","subject":"本公司受邀參加群益金鼎證券與IR Trust 共同舉辦之「再生醫療與消費醫療產業」論壇","clause":"第30款","fact_date":"2026-07-02","cite_as":"公開資訊觀測站重大訊息：路迦生醫（6814），2026-07-01 17:52，「本公司受邀參加群益金鼎證券與IR Trust 共同舉辦之「再生醫療與消費醫療產業」論壇」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7427-2026-07-01-1717-1350svj","company_id":"7427","company":"華上生醫","market":"興櫃","industry":"生技醫療","date":"2026-07-01","time":"17:17:10","subject":"公告本公司自主開發的Tucidinostat鹽類新藥GNTbm-CC-02，經審查取得墨西哥發明專利","clause":"第44款","fact_date":"2026-07-01","cite_as":"公開資訊觀測站重大訊息：華上生醫（7427），2026-07-01 17:17，「公告本公司自主開發的Tucidinostat鹽類新藥GNTbm-CC-02，經審查取得墨西哥發明專利」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6665-2026-07-01-1712-1qg80e5","company_id":"6665","company":"康聯生醫","market":"興櫃","industry":"生技醫療","date":"2026-07-01","time":"17:12:50","subject":"代重要子公司康儀科技股份有限公司公告法人董事與監察人改派代表人","clause":"第6款","fact_date":"2026-07-01","cite_as":"公開資訊觀測站重大訊息：康聯生醫（6665），2026-07-01 17:12，「代重要子公司康儀科技股份有限公司公告法人董事與監察人改派代表人」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2026-07-01-1701-1eilzlz","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2026-07-01","time":"17:01:40","subject":"代子公司TDW HK公告董事會決議增資迪瑞藥業(成都)有限公司","clause":"第20款","fact_date":"2026-07-01","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2026-07-01 17:01，「代子公司TDW HK公告董事會決議增資迪瑞藥業(成都)有限公司」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2026-07-01-1701-19jxlpw","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2026-07-01","time":"17:01:17","subject":"公告本公司擬增資100%子公司TDW HK Limited","clause":"第20款","fact_date":"2026-07-01","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2026-07-01 17:01，「公告本公司擬增資100%子公司TDW HK Limited」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2026-07-01-1700-o02v9u","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2026-07-01","time":"17:00:53","subject":"本公司依公開發行公司資金貸與及背書保證處理準則第二十二條第一項第三款之規定辦理公告","clause":"第23款","fact_date":"2026-07-01","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2026-07-01 17:00，「本公司依公開發行公司資金貸與及背書保證處理準則第二十二條第一項第三款之規定辦理公告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2026-07-01-1700-o9jske","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2026-07-01","time":"17:00:15","subject":"公告本公司申請股票上巿時所出具之承諾事項暨其後續執行情形","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2026-07-01 17:00，「公告本公司申請股票上巿時所出具之承諾事項暨其後續執行情形」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7850-2026-07-01-1635-1k07mxx","company_id":"7850","company":"寶泰生醫","market":"興櫃","industry":"生技醫療","date":"2026-07-01","time":"16:35:13","subject":"本公司受邀參加群益金鼎證券及IR Trust舉辦之「再生醫療與消費醫療產業論壇」","clause":"第30款","fact_date":"2026-07-02","cite_as":"公開資訊觀測站重大訊息：寶泰生醫（7850），2026-07-01 16:35，「本公司受邀參加群益金鼎證券及IR Trust舉辦之「再生醫療與消費醫療產業論壇」」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4771-2026-07-01-1624-16g7qjx","company_id":"4771","company":"望隼","market":"上市","industry":"生技醫療","date":"2026-07-01","time":"16:24:17","subject":"公告本公司初次申請股票上市時所出具之承諾事項暨其後續執行情形","clause":"第51款","fact_date":"2026-07-02","cite_as":"公開資訊觀測站重大訊息：望隼（4771），2026-07-01 16:24，「公告本公司初次申請股票上市時所出具之承諾事項暨其後續執行情形」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6876-2026-07-01-1553-c63gfi","company_id":"6876","company":"朗齊生醫*","market":"興櫃","industry":"生技醫療","date":"2026-07-01","time":"15:53:25","subject":"公告本公司技術長異動","clause":"第11款","fact_date":"2026-07-01","cite_as":"公開資訊觀測站重大訊息：朗齊生醫*（6876），2026-07-01 15:53，「公告本公司技術長異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-3705-2026-07-01-1539-uichiq","company_id":"3705","company":"永信","market":"上市","industry":"生技醫療","date":"2026-07-01","time":"15:39:29","subject":"公告本公司減少持有被控股公司家數","clause":"第41款","fact_date":"2026-07-01","cite_as":"公開資訊觀測站重大訊息：永信（3705），2026-07-01 15:39，「公告本公司減少持有被控股公司家數」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6576-2026-07-01-1523-ymb80","company_id":"6576","company":"逸達","market":"上櫃","industry":"生技醫療","date":"2026-07-01","time":"15:23:58","subject":"本公司新任商務長","clause":"第8款","fact_date":"2026-07-01","cite_as":"公開資訊觀測站重大訊息：逸達（6576），2026-07-01 15:23，「本公司新任商務長」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7729-2026-07-01-1515-1jwqxnp","company_id":"7729","company":"仲恩生醫","market":"興櫃","industry":"生技醫療","date":"2026-07-01","time":"15:15:18","subject":"公告本公司115年第一次現金增資催繳期間屆滿暨股票發放事宜","clause":"第44款","fact_date":"2026-07-01","cite_as":"公開資訊觀測站重大訊息：仲恩生醫（7729），2026-07-01 15:15，「公告本公司115年第一次現金增資催繳期間屆滿暨股票發放事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4911-2026-07-01-1437-jlvw2s","company_id":"4911","company":"德英","market":"上櫃","industry":"生技醫療","date":"2026-07-01","time":"14:37:31","subject":"公告本公司研發之新藥 SR-T100 注射劑(治療癌症惡性腹水)已正式向衛生福利部食品藥物管理署(TFDA)提出第一期人體臨床試驗(IND)申請","clause":"第53款","fact_date":"2026-07-01","cite_as":"公開資訊觀測站重大訊息：德英（4911），2026-07-01 14:37，「公告本公司研發之新藥 SR-T100 注射劑(治療癌症惡性腹水)已正式向衛生福利部食品藥物管理署(TFDA)提出第一期人」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6617-2026-07-01-0049-cbo6zy","company_id":"6617","company":"共信-KY","market":"上櫃","industry":"生技醫療","date":"2026-07-01","time":"00:49:51","subject":"代子公司共信醫藥科技股份有限公司公告向美國專利及商標局提出之專利申請案號：16/959,054 已獲核准通知","clause":"第53款","fact_date":"2026-06-30","cite_as":"公開資訊觀測站重大訊息：共信-KY（6617），2026-07-01 00:49，「代子公司共信醫藥科技股份有限公司公告向美國專利及商標局提出之專利申請案號：16/959,054 已獲核准通知」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}